KORU Medical’s FREEDOM Syringe Infusion System enables, simplifies, and enhances the delivery of large-volume subcutaneous drugs. Supporting drug products with various requirements for viscosity, flow ...

KORU Medical Systems Inc (KRMD) reports robust international expansion and increased revenue guidance despite domestic revenue decline and margin pressures.

Japanese drug major Takeda Friday announced new interim data from the Phase Ib, open-label, proof-of-concept study of ...

The narrative emphasizes the critical role of a supportive partner in managing chronic small lymphocytic lymphoma over 16 ...

Takeda presents new data showing mezagitamab sustained effect on kidney function 18 months after treatment in primary IgA nephropathy: Osaka, Japan Monday, November 10, 2025, 15:0 ...

Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 -- Reported highly ...

As of Monday, November 10, Vera Therapeutics, Inc.’s VERA share price has surged by 10.81%, which has investors questioning ...

The BLA submission, made through the FDA’s Accelerated Approval Program, follows positive results from the prespecified interim analysis of the ORIGIN 3 trial. The study met its primary endpoint, with ...

Leqembi® Approved For IV Maintenance Treatment In The United Kingdom. STOCKHOLM, Nov. 13, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqe ...

Viehbacher, “Biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (Aß) monoclonal antibody “LEQEMBI ® ” (generic name: lecanemab) has been approved for once every four weeks ...

But in findings presented at the American College of Allergy, Asthma and Immunology (ACAAI) meeting in Orlando, the novel ...

Johnson & Johnson ( JNJ) Guggenheim Securities 2nd Annual Healthcare Innovation Conference November 11, 2025 10:30 AM EST ...